Mezigdomide (MEZI) Plus Dexamethasone (DEX) and Daratumumab (DARA) or Elotuzumab (ELO) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Results from the CC-92480-MM-002 Trial

被引：7
|
作者：
Richardson, Paul G. [1 ]
Sandhu, Irwindeep [2 ]
Hofmeister, Craig C. [3 ]
Orlowski, Robert Z. [4 ]
White, Darrell [5 ,6 ]
Belotti, Angelo [7 ]
Hansen, Charlotte Toftmann [8 ]
Raje, Noopur S. [9 ]
Chow, Tracy T. [10 ]
Zhou, Zehua [10 ]
Civardi, Tiziana [11 ]
Koo, Phillip [10 ]
Zhu, Yue [10 ]
Katz, Jessica [10 ]
Oriol, Albert [12 ,13 ]
机构：
[1] Dana Farber Canc Inst, Boston, MA USA
[2] Cross Canc Inst, Edmonton, AB, Canada
[3] Winship Canc Inst Emory Univ, Atlanta, GA USA
[4] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma & Myeloma, Houston, TX USA
[5] Dalhousie Univ, Halifax, NS, Canada
[6] Queen Elizabeth 2 Hlth Sci Ctr, Halifax, NS, Canada
[7] ASST Spedali Civili Brescia, Dept Hematol, Brescia, Italy
[8] Odense Univ Hosp, Odense, Denmark
[9] Massachusetts Gen Hosp, Boston, MA USA
[10] Bristol Myers Squibb, Princeton, NJ USA
[11] Bristol Myers Squibb Co, Celgene Int Sarl, Boudry, Switzerland
[12] Hosp Germans Trias i Pujol, Catalan Inst Oncol, Badalona, Spain
[13] Hosp Germans Trias i Pujol, Josep Carreras Inst, Badalona, Spain
来源：
BLOOD | 2023年 / 142卷
关键词：
D O I：
10.1182/blood-2023-174443
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：5
相关论文
共 50 条
  • [31] Melflufen in patients (pts) with relapsed/refractory multiple myeloma (RRMM) refractory to daratumumab (dara) and/or pomalidomide (pom) (OP-106)
    Richardson, Paul G.
    Oriol, Albert
    Larocca, Alessandra
    Rodriguez Otero, Paula
    Moreb, Jan
    Blade, Joan
    Hassoun, Hani
    Cavo, Michele
    Alegre, Adrian
    Mazumder, Amitabha
    Maisel, Christopher
    Paner, Agne
    Leleu, Xavier
    Zonder, Jeffrey A.
    Harmenberg, Johan
    Thuresson, Sara
    Zubair, Hanan
    Mateos, Maria-Victoria
    CANCER RESEARCH, 2019, 79 (13)
  • [32] Impact of renal impairment (RI) on pharmacokinetics (PK) and clinical outcomes with mezigdomide plus dexamethasone (DEX) in relapsed/refractory multiple myeloma (RRMM)
    Trudel, Suzanne
    Bahlis, Nizar J.
    Popat, Rakesh
    Mateos, Maria-Victoria
    Vangsted, Annette J.
    Ramasamy, Karthik
    Martinez-Lopez, Joaquin
    Quach, Hang
    Orlowski, Robert Z.
    Burnett, Joseph
    Gaudy, Allison
    Chen, Wencong
    Gong, Jing
    Hadala, Joseph T.
    Donahue, Cynthia
    Koo, Phillip
    Zhu, Yue
    Katz, Jessica
    Richardson, Paul G.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [33] ELOQUENT-2: A phase III, randomized, open-label study of lenalidomide (Len)/dexamethasone (dex) with/without elotuzumab (Elo) in patients (pts) with relapsed/refractory multiple myeloma (RRMM).
    Lonial, Sagar
    Dimopoulos, Meletios A.
    Palumbo, Antonio
    White, Darrell
    Grosicki, Sebastian
    Spicka, Ivan
    Walter-Croneck, Adam
    Moreau, Philippe
    Mateos, Maria-Victoria
    Magen-Nativ, Hila
    Belch, Andrew
    Reece, Donna Ellen
    Beksac, Meral
    Taniwaki, Masafumi
    Roellig, Christoph
    Singhal, Anil K.
    Katz, Jessica
    Bleickardt, Eric W.
    Poulart, Valerie
    Richardson, Paul G.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [34] Phase II Trial of Elotuzumab with Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma (RRMM) in the Post-Daratumumab Progression Setting
    Ailawadhi, Sikander
    Parrondo, Ricardo D.
    Laplant, Betsy
    Alegria, Victoria R.
    Elliott, Jamie B.
    Sher, Taimur
    Paulus, Aneel
    Chapin, Dustin
    Heslop, Keisha
    Chanan-Khan, Asher
    Roy, Vivek
    BLOOD, 2022, 140 : 4450 - 4451
  • [35] A phase II randomized study of bortezomib/dexamethasone (Bort/Dex) with or without elotuzumab (Elo) in patients (pts) with relapsed/refractory multiple myeloma (RR MM) (CA204-009).
    Jakubowiak, Andrzej J.
    White, Darrell
    Moreau, Philippe
    Facon, Thierry
    Vij, Ravi
    Kroog, Glenn Scott
    Kopit, Justin
    Singhal, Anil
    Palumbo, Antonio Pierangelo
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [36] Results of Study CC-220-MM-001 Dose Expansion of Iberdomide (IBER) in Combination with Dexamethasone (DEX) in Patients with Relapsed/Relapsed-Refractory Multiple Myeloma (RRMM)
    Knop, S.
    Lonial, S.
    Popat, R.
    Hulin, C.
    Jagannath, S.
    Oriol, A.
    Richardson, P. G.
    Facon, T.
    Weisel, K.
    Larsen, J. T.
    Minnema, M. C.
    Abdallah, A. -O. A.
    Badros, A. Z.
    Stadtmauer, E. A.
    Chen, M.
    Nguyen, T., V
    Amin, A.
    Peluso, T.
    van de Donk, N. W. C. J.
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 2) : 247 - 247
  • [37] Talquetamab (tal) plus Daratumumab (dara) plus Pomalidomide (pom) in Patients (pts) With Relapsed/Refractory Multiple Myeloma (RRMM): Results from the Phase 1b TRIMM-2 Study
    Bahlis, Nizar J.
    de Donk, Niels van
    Reece, Donna
    Bhutani, Manisha
    Dholaria, Bhagirathbhai
    D'Souza, Anita
    Martin, Thomas
    McKay, John
    Garfall, Alfred
    Krishnan, Amrita
    Bakshi, Kalpana
    Kang, Lijuan
    Vandenberk, Lien
    Prior, Thomas
    Tolbert, Jaszianne
    Chari, Ajai
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S1 - S1
  • [38] Ixazomib (IXA), carfilzomib (CAR), elotuzumab (ELO) or daratumumab (DAR) with lenalidomide and dexamethasone (LEN plus DEX) versus LEN plus DEX only in relapsed/refractory multiple myeloma (R/R MM): A comparative cost-effectiveness analysis.
    Obeng-Kusi, Mavis
    Arku, Daniel
    Alrawashdh, Neda
    Choi, Briana
    Alkhatib, Nimer S.
    McBride, Ali
    Abraham, Ivo
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [39] Pomalidomide, Cyclophosphamide and Dexamethasone (PCD) is an effective salvage regimen for multiple myeloma (MM) patients relapsed and/or refractory to Daratumumab (dara)
    Brioli, A.
    Ernst, T.
    Hilgendorf, I.
    Heidel, F.
    Hunstig, F.
    Stauch, T.
    Hochhaus, A.
    von Lilienfeld-Toal, M.
    ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 : 278 - 278
  • [40] Long-Term Outcomes and Safety of Continuous Lenalidomide Plus Dexamethasone (Len plus Dex) Treatment in Patients (Pts) with Relapsed or Refractory Multiple Myeloma (RRMM)
    Dimopoulos, Meletios Athanasios
    Hussein, Mohamad
    Swern, Arlene S.
    Weber, Donna M.
    BLOOD, 2011, 118 (21) : 1263 - 1263
12345